Discovery of protein-protein binding disruptors using multi-component condensations small molecules

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 15, 2006, Pages 3998-4001

  Bedjeguelal, Karim ^a   Bienaymé, Hugues ^a   Dumoulin, Antoine ^a   Poigny, Stéphane ^a   Schmitt, Philippe ^a   Tam, Eric ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

3 Amino 1 cyano indolizines; Multi component condensations; Protein protein interaction; VEGF NRP1

Indexed keywords

INDOLIZINE DERIVATIVE; NEUROPILIN 1; NITRILE; VASCULOTROPIN;

ARTICLE; CHEMICAL REACTION; DRUG ACTIVITY; DRUG DETERMINATION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MULTI COMPONENT CONDENSATION; POLYMERIZATION; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION;

CELL LINE; NEUROPILIN-1; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745142254     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.05.014     Document Type: Article

References (24)

1. Soker S., Takashima S., Miao H.Q., Neufeld G., and Klagsbrun M. Cell 92 (1998) 735
2. He Z., and Tessier-Lavigne M. Cell 90 (1997) 739
3. Results to be published elsewhere.
4. Various approaches have been tested in order to selectively inhibit the VEGF pathway. Soluble VEGF receptors (i.e. VEGF-Trap) have shown a powerful and selective antitumor action, whereas VEGF specific antibody Avastin has been successfully used as a therapeutic in several cancer indications. Other strategies focus on inhibiting the kinase activity of VEGFR2 in order to annihilate the VEGF effect.
5. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., and Liu E.A. Science 303 (2004) 844
6. Grasberger B.L., Lu T., Schubert C., Parks D.J., Carver T.E., Koblish H.K., Cummings M.D., LaFrance L.V., Milkiewicz K.L., Calvo R.R., Maguire D., Lattanze J., Franks C.F., Zhao S.-Y., Ramachandren K., Bylebyl G.R., Zhang M., Manthey C.L., Petrella E.C., Pantoliano M.W., Deckman I.C., Spurlino J.C., Maroney A.C., Tomczuk B.E., Molloy C.J., and Bone R.F. J. Med. Chem. 48 (2005) 909
7. Parks D.J., LaFrance L.V., Calvo R.R., Milkiewicz K.L., Gupta V., Lattanze J., Ramachandren K., Carver T.E., Petrella E.C., Cummings M.D., Maguire D., Grasberger B.L., and Lu T. Biorg. Med. Chem. Lett. 15 (2005) 765
8. Degterev A., Lugovskoy A., Cardone M., Mulley B., Wagner G., Mitchison T., and Yuan J. Nat. Cell Biol. 3 (2001) 173
9. Tzung S.P., Kim K.M., Basanez G., Giedt C.D., Simon J., Zimmerberg J., Zhang K.Y., and Hockenbery D.M. Nat. Cell Biol. 3 (2001) 183
10. For additional examples of small molecules antagonizing protein-protein interactions, see;. Gadek T.R., and Nicholas J.B. Biochem. Pharmacol. 65 (2003) 1
11. Toogood P.L. J. Med. Chem. 45 (2002) 1543
12. Dömling A., and Ugi I. Angew. Chem. Int. Ed. 39 (2000) 3168
13. Bienaymé H., Hulme C., Oddon G., and Schmitt P. Chem. Eur. J. 6 (2000) 3321
14. Zhu J. Eur. J. Org. Chem. 7 (2003) 1133
15. Zhu J., and Bienayme H. Multicomponent Reactions (2005), Wiley-VCH, Weinheim
16. See for instance:. Zhao G., Sun X., Bienaymé H., and Zhu J. J. Am. Chem. Soc 123 (2001) 6700
17. Janvier P., Sun X., Bienaymé H., and Zhu J. J. Am. Chem. Soc. 124 (2002) 2560
18. ELISA test: Neuropilin 1 was expressed in a baculovirus system as a soluble form able to bind VEGF165, purified from High Five insect cells, and stored at -80 °C in 50% glycerol. VEGF165 was bought from R&D Systems and stored at -80 °C. The screening procedure is based on an ELISA test with Nrp1 coated on the plates and VEGF165 added for the binding assay. After several washing steps, an anti-VEGF antibody is used to detect the level of interaction between the two proteins. Detection is based on luminescence generated by an enzyme (HRP) coupled to the antibody.
19. Bedjeguelal, K.; Bienaymé, H.; Schmitt, P.; Grisoni, S. PCT Int. Appl. WO 2,004,108,722, 2004;.
20. Bedjeguelal, K.; Bienaymé, H.; Poigny, S.; Schmitt, P.; Tam, E. QSAR Combi. Sci. 2006, in press.
21. For a similar mechanism-based three-component condensation, see:. Bienaymé H., and Bouzid K. Angew. Chem. Int. Ed. 37 (1998) 2234
22. Bon R.S., Vliet B.V., Sprenkels N.E., Schmitz R.B., de Kanter F.J., Stevens C.V., Swart M., Bickelhaupt F.M., Groen M.B., and Orru R.V.A. J. Org. Chem. 70 (2005) 3542
23. Fong C.J., Sutkowski D.M., Kozlowski J.M., and Lee C. Invasion Metastasis 12 (1992) 264
24. These activities were not the consequence of a general toxicity, as the compounds failed to show any toxicity in a LDH-release assay.